Clinical Trial Update: Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 trial investigating peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients with hepatocellular carcinoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Chronic Hepatitis C, Hepatocellular Carcinoma | Phase 4 | Status: UNKNOWN